Key Papers
2025
Topical supplementation with physiologic lipids rebalances the stratum corneum ceramide profile and strengthens skin barrier function in adults predisposed to atopic dermatitis
Andrew PV, Williams SF, Brown K, Chittock J, Pinnock A, Poyner A, Cork MJ, Danby SG (2025)
Is colloidal oat an effective emollient ingredient for the prevention and treatment of atopic dermatitis in infants?
Fowler JF, Ma L, Bergman J, Horowitz P, Lavender T, Eichenfield LF, Draelos Z, Danby SG, Cork MJ (2025)
Management of Mild-to-Moderate Atopic Dermatitis With Topical Treatments by Dermatologists: A Questionnaire-Based Study
Eichenfield LF, Stein Gold LF, Hebert AA, Guenther L, Valdman-Grinshpoun Y, Ben-Amitai D, Dodiuk-Gad RP, Cork MJ, Aoki V, Chu C-Y, Zhang J, Ma L, Saeki H, Luna PC, Koh MJ-A (2025)
Dupilumab Treatment Improves Lichenification in Atopic Dermatitis in Different Age and Racial Groups
Guttman-Yassky E, Katoh N, Cork MJ, Jagdeo J, Alexis AF, Chen Z, Levit NA, Rossi AB (2025)
2024
Real-Time In Vivo Human Skin Testing Using a Handheld Fourier Transform Infrared Spectrometer with a Three-Bounce Two-Pass Attenuated Total Reflection Interface
Williams SF, Chittock J, Brown K, Kay LJ, Cork MJ, Danby SG (2024)
Low Infection Rates With Long-Term Dupilumab Treatment in Patients Aged 6 Months to 5 Years: An Open-Label Extension Study
Paller AS, Ramien M, Cork MJ, Simpson EL, Wine Lee L, Eichenfield LF, Khokhar FA, Coleman A, Gherardi G, Chen Z, Zhang A, Cyr SL (2024)
Durable improvements in atopic dermatitis in the head and neck and across other anatomic regions with rocatinlimab
Guttman-Yassky E, Esfandiari E, Mano H, Arai T, Irvine AD, Cork MJ, Kabashima K, Chong C, Simpson E (2024)
Practicality, Validity, and Responsiveness of Using the Proxy Version of the Child Health Utility-9 Dimensions With Children Aged 2 to 5 Years
Sach TH, Williams HC; BEEP study team; Allen H, Boyle R, Kelleher M, Brown S, Cork M, Flohr C, Jay N, Lartey S, Davies C, Lawton S, Perkin M, Ridd M, Sach T, Brooks J, Haines R, Mitchell E, Montgomery A, Swinden R, Tarr S, Wyatt L, Thomas K, Williams H, Chalmers J, Davies-Jones S (2024)
The effect of dupilumab on caregiver- and patient-reported outcomes in young children with moderate-to-severe atopic dermatitis: results from a placebo-controlled, phase 3 study
Paller AS, Silverberg JI, Simpson EL, Cork MJ, Arkwright PD, Chen Z, Bansal A, Prescilla R, Wang Z, Marco AR (2024)
Novel biophysical skin biomarkers discriminate topical anti-inflammatory treatments based on their potential for local adverse effects
Danby SG, Matcher S, Byers R, Taylor R, Sahib S, Andrew P, Brown K, Kay L, Wright C, Pinnock A, Chittock J, Duan M, Cha A, Adiri R, Zang C, Werth J, Cork MJ (2024)
A Practical Guide to Using Oral JAK Inhibitors for Atopic Dermatitis from the International Eczema Council
Haag C, Alexis A, Aoki V, Bissonnette R, Blauvelt A, Chovatiya R, Cork MJ, Danby SG, Eichenfield L, Eyerich K, Gooderham M, Guttman-Yassky E, Hijnen DJ, Irvine A, Katoh N, Murrell DF, Leshem YA, Levin A, Vittrup I, Olydam JI, Orfali RL, Paller A, Renert-Yuval Y, Rosmarin D, Silverberg J, Thyssen J, Ständer S, Stefanovic N, Todd G, Yu J, Simpson E (2024)
Refractory pyoderma gangrenosum in Caucasian adolescent with Takayasu arteritis and life-threatening infections
Yeo TF, Labbouz S, Lawrance N, Sitaraaman H, Tattersall RS, Cork MJ (2024)
Effects of a pH-Regulating Emollient Cream in Mild Atopic Dermatitis Patients with Moderate Localized Lesions
Ng SP, Bielfeldt S, Laing S, Danby S, Cork MJ (2024)
Pharmacokinetics and pharmacodynamics of itepekimab in adults with moderate-to-severe atopic dermatitis: Results from two terminated phase II trials
Kosloski MP, Guttman-Yassky E, Cork MJ, Worm M, Nahm DH, Zhu X, Ruddy MK, Harel S, Kamal MA, Goulaouic H, Xu CR, Avetisova E, Davis JD, Nivens MC, Shabbir A, Radin A (2024)
A prospective observational cohort study comparing the treatment effectiveness and safety of ciclosporin, dupilumab and methotrexate in adult and paediatric patients with atopic dermatitis: results from the UK-Irish A-STAR register
Alexander H, Malek R, Prieto-Merino D, Gribaleva E, Baden M, Beattie P, Brown S, Burton T, Cameron S, Coker B, Cork MJ, Hearn R, Ingram JR, Irvine AD, Johnston GA, Lambert A, Lunt M, Man I, Newell L, Ogg G, Patel P, Wan M, Warren RB, Woolf R, Yiu ZZN, Reynolds N, Ardern-Jones MR, Flohr C; UK-Irish A-STAR Study Group (2024)
The effects of ciclosporin and methotrexate on kidney function in the treatment of severe atopic dermatitis in children - results from the TREAT trial
Bruce G, Rosala-Hallas A, Jones AP, Turner C, Dalton N, Hilger E, Baron S, Beattie P, Browne F, Brown SJ, Gach JE, Hearn R, Esdaile B, Cork MJ, Howard E, Greenblatt D, August S, Lovgren ML, Ashoor F, Williamson P, McPherson T, O'Kane D, Ravenscroft J, Shaw L, Spowart C, Thomas BR, Sach T, Wan M, Irvine AD, Sinha MD, Flohr C (2024)
Emollient application from birth to prevent eczema in high-risk children: the BEEP RCT
Bradshaw LE, Wyatt LA, Brown SJ, Haines RH, Montgomery AA, Perkin MR, Sach TH, Lawton S, Flohr C, Ridd MJ, Chalmers JR, Brooks J, Swinden R, Mitchell EJ, Tarr S, Jay N, Thomas KS, Allen H, Cork MJ, Kelleher MM, Simpson EL, Lartey ST, Davies-Jones S, Boyle RJ, Williams HC (2024)
Practical Management of the JAK1 Inhibitor Abrocitinib for Atopic Dermatitis in Clinical Practice: Special Safety Considerations
Gooderham MJ, de Bruin-Weller M, Weidinger S, Cork MJ, Eichenfield LF, Simpson EL, Tsianakas A, Kerkmann U, Feeney C, Romero W (2024)
Dupilumab Safety and Efficacy up to 1 Year in Children Aged 6 Months to 5 Years with Atopic Dermatitis: Results from a Phase 3 Open-Label Extension Study
Paller AS, Siegfried EC, Simpson EL, Cork MJ, Sidbury R, Chen IH, Khokhar FA, Xiao J, Dubost-Brama A, Bansal A (2024)
Infections in Children Aged 6 Months to 5 Years Treated with Dupilumab in a Placebo-Controlled Clinical Trial of Moderate-to-Severe Atopic Dermatitis
Paller AS, Siegfried EC, Cork MJ, Arkwright PD, Eichenfield LF, Ramien M, Khokhar FA, Chen Z, Zhang A, Cyr SL (2024)
Clinically Meaningful Responses to Dupilumab Among Children Aged 6 Months to 5 Years with Moderate-to-severe Atopic Dermatitis who did Not Achieve Clear or Almost Clear Skin According to the Investigator’s Global Assessment: A Post Hoc Analysis of a Phase 3 Trial
Cork MJ, Lockshin B, Pinter A, Chen Z, Shumel B, Prescilla R (2024)
Dupilumab Treatment in Pediatric Patients Aged 6-11 Years with Severe Atopic Dermatitis Whose Disease Is Not Adequately Controlled: A Review
Cork MJ, Danby SG, Rossi AB, Bansal A (2024)
Maintenance of an Acidic Skin Surface with a Novel Zinc Lactobionate Emollient Preparation Improves Skin Barrier Function in Patients with Atopic Dermatitis (Barrier 2 Study)
Andrew PV, Pinnock A, Poyner A, Brown K, Chittock J, Kay LJ, Cork MJ, Danby SG (2024)
2023
Characterisation of skin barrier defects in atopic dermatitis patients using Infrared Spectroscopy
Williams SF, Wan H, Chittock J, Brown K, Wigley A, Cork MJ, Danby SG (2023)
Association Between Skin Barrier Development and Early-Onset Atopic Dermatitis: A Longitudinal Birth Cohort Study
Chittock J, Kay L, Brown K, Cooke A, Lavender T, Cork MJ, Danby SG (2023)
Tralokinumab Provides Clinically Meaningful Responses at Week 16 in Adults with Moderate-to-Severe Atopic Dermatitis Who Do Not Achieve IGA 0/1
Simpson EL, Blauvelt A, Silverberg JI, Cork MJ, Katoh N, Mark T, Schneider SKR, Wollenberg A (2023)
Dupilumab Safety and Efficacy in a Phase III Open-Label Extension Trial in Children 6-11 Years of Age with Severe Atopic Dermatitis
Cork MJ, Thaçi D, Eichenfield LF, Arkwright PD, Chen Z, Thomas RB, Kosloski MP, Dubost-Brama A, Prescilla R, Bansal A, Levit NA (2023)
Efficacy and safety of ciclosporin versus methotrexate in the treatment of severe atopic dermatitis in children and young people (TREAT): a multicentre, parallel group, assessor-blinded clinical trial
Flohr C, Rosala-Hallas A, Jones AP, Beattie P, Baron S, Browne F, Brown SJ, Gach JE, Greenblatt D, Hearn R, Hilger E, Esdaile B, Cork MJ, Howard E, Lovgren ML, August S, Ashoor F, Williamson PR, McPherson T, O'Kane D, Ravenscroft J, Shaw L, Sinha MD, Spowart C, Taams LS, Thomas BR, Wan M, Sach TH, Irvine AD (2023)
A concept for integrated care pathways for atopic dermatitis—A GA2LEN ADCARE initiative
Torsten Zuberbier, Amir Abdul Latiff, Xenofon Aggelidis, Matthias Augustin, Radu-Gheorghe Balan, Christine Bangert, Lisa Beck, Thomas Bieber, Jonathan A. Bernstein, Marta Bertolin Colilla, Alejandro Berardi, Anna Bedbrook, Carsten Bindslev-Jensen, Jean Bousquet, Marjolein de Bruin-Weller, Dayanne Bruscky, Betul Buyuktiryaki, Giorgio Walter Canonica, Carla Castro, Natia Chanturidze, Herberto Jose Chong-Neto, Chia-Yu Chu, Leena Chularojanamontri, Michael Cork, Roberta F. J. Criado, Laia Curto Barredo, Adnan Custovic, Ulf Darsow, Arben Emurlai, Ana de Pablo, Stefano Del Giacco, Giampiero Girolomoni, Tanja Deleva Jovanova, Mette Deleuran, Nikolaos Douladiris, Bruno Duarte, Ruta Dubakiene, Esben Eller, Batya Engel-Yeger, Luis Felipe Ensina, Nelson Rosario Filho, Carsten Flohr, Daria Fomina, Wojciech Francuzik, Maria Laura Galimberti, Ana M. Giménez-Arnau, Kiran Godse, Charlotte Gotthard Mortz, Maia Gotua, Michihiro Hide, Wolfram Hoetzenecker, Nicolas Hunzelmann, Alan Irvine, Carolyn Jack, Ioanna Kanavarou, Norito Katoh, Tamar Kinaciyan, Emek Kocatürk, Kanokvalai Kulthanan, Hilde Lapeere, Susanne Lau, Mariana Machado Forti Nastri, Michael Makris, Eli Mansour, Alexander Marsland, Mara Morelo Rocha Felix, Ana Paula Moschione Castro, Eustachio Nettis, J. F. Nicolas, Audrey Nosbaum, Mikaela Odemyr, Niki Papapostolou, Claudio A. S. Parisi, Sushil Paudel, Jonny Peter, Prakash Pokharel, Luis Puig, Tamara Quint, German Dario Ramon, Frederico Regateiro, Giampaolo Ricci, Cristine Rosario, Cansin Sackesen, Peter Schmid-Grendelmeier, Esther Serra-Baldrich, Kristina Siemens, Cathrine Smith, Petra Staubach, Katarina Stevanovic, Özlem Su-Kücük, Gordon Sussman, Simona Tavecchio, Natasa Teovska Mitrevska, Diamant Thaci, Elias Toubi, Claudia Traidl-Hoffmann, Regina Treudler, Zahava Vadasz, Ingrid van Hofman, Maria Teresa Ventura, Zhao Wang, Thomas Werfel, Andreas Wollenberg, Ariana Yang, Yik Weng Yew, Zuotao Zhao, Ricardo Zwiener, Margitta Worm (2023)
Emollients for preventing atopic eczema: Cost-effectiveness analysis of the BEEP trial
Sach TH, Lartey ST, Davies C, Chalmers JR, Haines RH, Bradshaw LE, Montgomery AA, Thomas KS, Brown SJ, Ridd MJ, Lawton S, Cork MJ, Flohr C, Mitchell E, Swinden R, Wyatt L, Tarr S, Davies-Jones S, Jay N, Kelleher MM, Perkin MR, Boyle RJ, Williams HC; BEEP Study Team (2023)
Dupilumab Treatment Leads to Rapid and Consistent Improvement of Atopic Dermatitis in All Anatomical Regions in Patients Aged 6 Months to 5 Years
Siegfried EC, Simpson EL, Cork MJ, Arkwright PD, Wine Lee L, Chen Z, Prescilla R, Bansal A, Levit NA, Rodríguez Marco A (2023)
Safety and efficacy of amlitelimab, a fully human, non-depleting, non-cytotoxic anti-OX40Ligand monoclonal antibody, in atopic dermatitis: results of a phase IIa randomised placebo-controlled trial
Weidinger S, Bieber T, Cork MJ, Reich A, Wilson R, Quaratino S, Stebegg M, Brennan N, Gilbert S, O'Malley JT, Porter-Brown B (2023)
Potential application of PS-OCT in the safety assessment of non-steroidal topical creams for atopic dermatitis treatment
Duan MQ, Byers RA, Danby SG, Sahib S, Cha A, Zang C, Werth J, Adiri R, Taylor RN, Cork MJ, Matcher SJ (2023)
Dupilumab Provides Clinically Meaningful Responses in Children Aged 6–11 Years with Severe Atopic Dermatitis: Post Hoc Analysis Results from a Phase III Trial
Siegfried EC, Cork MJ, Katoh N, Zhang H, Chuang CC, Thomas RB, Rossi AB, Cyr SL, Zhang A (2023)
Are mild cleansers appropriate for hand hygiene in the COVID era? An in vitro investigation of the antiviral efficacy of different hand hygiene products
Winder N, Ashraf Z, Gohar S, Baalbaki N, Cork M, Danby S, Muthana M (2023)
Efficacy and Safety of Abrocitinib in Patients with Severe and/or Difficult-to-Treat Atopic Dermatitis: A Post Hoc Analysis of the Randomized Phase 3 JADE COMPARE Trial
Simpson EL, Silverberg JI, Thyssen JP, Viguier M, Thaçi D, de Bruin-Weller M, Weidinger S, Chan G, DiBonaventura M, Biswas P, Feeney C, Koulias C, Cork MJ (2023)
Dupilumab improves patient-reported symptoms and health-related quality of life in children aged 6-11 years with severe atopic dermatitis
Flohr C, Irvine AD, Cork MJ, Simpson EL, Wollenberg A, Deleuran M, Praestgaard A, Thomas RB, Rossi AB (2023)
The Importance of a Healthy Skin Barrier From the Cradle to the Grave Using Ceramide-Containing Cleansers and Moisturizers: A Review and Consensus
Schachner L, Alexis A, Andriessen A, Baldwin H, Cork M, Kirsner R, Woolery-Lloyd H (2023)
Efficacy and Safety of Tralokinumab in Adolescents With Moderate to Severe Atopic Dermatitis: The Phase 3 ECZTRA 6 Randomized Clinical Trial
Paller AS, Flohr C, Cork M, Bewley A, Blauvelt A, Hong HC, Imafuku S, Schuttelaar MLA, Simpson EL, Soong W, Arlert P, Lophaven KW, Kurbasic A, Soldbro L, Vest NS, Wollenberg A (2023)
Efficacy and Safety of Abrocitinib Monotherapy in Adolescents and Adults: A Post Hoc Analysis of the Phase 3 JAK1 Atopic Dermatitis Efficacy and Safety (JADE) REGIMEN Clinical Trial
Flohr C, Cork MJ, Ardern-Jones MR, Eichenfield LF, Barbarot S, Feeney C, Rojo R, Lazariciu I, Nesnas J (2023)
Early improvements in signs and symptoms predict clinical response to baricitinib in patients with moderate-to-severe atopic dermatitis
Bieber T, Thyssen JP, Irvine AD, Tsunemi Y, Chen YF, Sun L, Schloebe A, Riedl E, Cork MJ (2023)
Developing integrated care pathways for atopic dermatitis—Challenges and unmet needs
Zuberbier T, Beck LA, Bedbrook A, de Bruin-Weller M, Bousquet J, Cork M, Douladiris N, Katoh N, Mortz CG, Werfel T, Wojciech F, Wollenberg A, Siemens K, Stevanovic K, Worm M; AD-ICPs Working Group (2023)
Supplement Individual Article: The Importance of a Healthy Skin Barrier From the Cradle to the Grave Using Ceramide-Containing Cleansers and Moisturizers: A Review and Consensus
Schachner L, Alexis A, Andriessen A, Baldwin H, Cork M, Kirsner R, Woolery-Lloyd H (2023)
Efficacy and Safety of Dupilumab in Patients With Erythrodermic Atopic Dermatitis: A Post Hoc Analysis of 6 Randomized Clinical Trials
Paller AS, Silverberg JI, Cork MJ, Guttman-Yassky E, Lockshin B, Irvine AD, Kim MB, Kabashima K, Chen Z, Lu Y, Bansal A, Rossi AB, Shabbir A (2023)
2022
Laboratory Safety from a Randomized 16-Week Phase III Study of Dupilumab in Children Aged 6 Months to 5 Years with Moderate-to-Severe Atopic Dermatitis
Paller AS, Siegfried EC, Cork MJ, Wollenberg A, Arkwright PD, Gonzalez ME, Lockshin B, Chen Z, Bansal A, Levit NA, Prescilla R (2022)
Type 2 Inflammation Contributes to Skin Barrier Dysfunction in Atopic Dermatitis
Beck LA, Cork MJ, Amagai M, De Benedetto A, Kabashima K, Hamilton JD, Rossi AB (2022)
A real-world retrospective observational study exploring NHS resource use in England for the management of moderate-to-severe atopic dermatitis in secondary care for children and adolescents
McPherson T, Cork MJ, Goodhead C, Michaelis LJ, Flohr C, Petrovic M, Hennessy L, Rajkovic I, Hudson R (2022)
Dupilumab in children aged 6 months to younger than 6 years with uncontrolled atopic dermatitis: a randomised, double-blind, placebo-controlled, phase 3 trial
Paller AS, Simpson EL, Siegfried EC, Cork MJ, Wollenberg A, Arkwright PD, Soong W, Gonzalez ME, Schneider LC, Sidbury R, Lockshin B, Meltzer S, Wang Z, Mannent LP, Amin N, Sun Y, Laws E, Akinlade B, Dillon M, Kosloski MP, Kamal MA, Dubost-Brama A, Patel N, Weinreich DM, Yancopoulos GD, O'Malley JT, Bansal A (2022)
Long-Term Efficacy and Safety of Dupilumab in Adolescents with Moderate-to-Severe Atopic Dermatitis: Results Through Week 52 from a Phase III Open-Label Extension Trial (LIBERTY AD PED-OLE)
Blauvelt A, Guttman-Yassky E, Paller AS, Simpson EL, Cork MJ, Weisman J, Browning J, Soong W, Sun X, Chen Z, Kosloski MP, Kamal MA, Delevry D, Chuang CC, O'Malley JT, Bansal A (2022)
Moisturizer therapy in prevention of atopic dermatitis and food allergy: To use or disuse?
Katibi OS, Cork MJ, Flohr C, Danby SG (2022)
Different types of emollient cream exhibit diverse physiological effects on the skin barrier in adults with atopic dermatitis
Danby SG, Andrew PV, Taylor RN, Kay LJ, Chittock J, Pinnock A, Ulhaq I, Fasth A, Carlander K, Holm T, Cork MJ (2022)
Infections in children and adolescents treated with dupilumab in pediatric clinical trials for atopic dermatitis - A pooled analysis of trial data
Paller AS, Beck LA, Blauvelt A, Siegfried EC, Cork MJ, Wollenberg A, Chen Z, Khokhar FA, Vakil J, Zhang A, Bansal A, Cyr SL (2022)
Enhancement of stratum corneum lipid structure improves skin barrier function and protects against irritation in adults with dry, eczema-prone skin
Danby SG, Andrew PV, Kay LJ, Pinnock A, Chittock J, Brown K, Williams SF, Cork MJ (2022)
Randomized controlled pilot trial with ion-exchange water softeners to prevent eczema (SOFTER trial)
Jabbar-Lopez ZK, Ezzamouri B, Briley A, Greenblatt D, Gurung N, Chalmers JR, Thomas KS, Frost T, Kezic S, Common JEA, Danby S, Cork MJ, Peacock JL, Flohr C (2022)
Impact of oral abrocitinib on signs, symptoms and quality of life among adolescents with moderate-to-severe atopic dermatitis: an analysis of patient-reported outcomes
Cork MJ, McMichael A, Teng J, Valdez H, Rojo R, Chan G, Zhang F, Myers DE, DiBonaventura M (2022)
Effect of seasonal change on the biomechanical and physical properties of the human skin
Uchegbulam I, Danby SG, Lewis R, Carré MJ, Maiti R (2022)
Proposal of 0.5 mg of protein/100 g of processed food as threshold for voluntary declaration of food allergen traces in processed food-A first step in an initiative to better inform patients and avoid fatal allergic reactions: A GA²LEN position paper
Zuberbier T, Dörr T, Aberer W, Alvaro M, Angier E, Arasi S, Arshad H, Ballmer-Weber B, Bartra J, Beck L, Bégin P, Bindslev-Jensen C, Bislimovska J, Bousquet J, Brockow K, Bush A, Cianferoni A, Cork MJ, Custovic A, Darsow U, de Jong N, Deleanu D, Del Giacco S, Deschildre A, Dunn Galvin A, Ebisawa M, Fernández-Rivas M, Ferrer M, Fiocchi A, Gerth van Wijk R, Gotua M, Grimshaw K, Grünhagen J, Heffler E, Hide M, Hoffmann-Sommergruber K, Incorvaia C, Janson C, Malte John S, Jones C, Jutel M, Katoh N, Kendziora B, Kinaciyan T, Knol E, Kurbacheva O, Lau S, Loh R, Lombardi C, Mäkelä M, Marchisotto MJ, Makris M, Maurer M, Meyer R, Mijakoski D, Minov J, Mullol J, Nilsson C, Nowak-Wegrzyn A, Nwaru BI, Odemyr M, Pajno GB, Paudel S, Papadopoulos NG, Renz H, Ricci G, Ring J, Rogala B, Sampson H, Senna G, Sitkauskiene B, Smith PK, Stevanovic K, Stoleski S, Szajewska H, Tanaka A, Todo-Bom A, Topal FA, Valovirta E, Van Ree R, Venter C, Wöhrl S, Wong GWK, Zhao Z, Worm M (2022)
2021
Response to: Letter to the Editor Regarding "An Investigation of the Skin Barrier Restoring Effects of a Cream and Lotion Containing Ceramides in a Multi-Vesicular Emulsion in People with Dry, Eczema-Prone, Skin: The RESTORE Study Phase 1"
Danby SG, Andrew PV, Brown K, Chittock J, Kay LJ, Cork MJ (2021)
Efficacy and safety of crisaborole in patients with mild-to-moderate atopic dermatitis and other atopic comorbidities
Spergel JM, Blaiss MS, Lio P, Kessel A, Cantrell WC, Takiya L, Werth JL, O'Connell MA, Zang C, Cork MJ (2021)
Laboratory Safety of Dupilumab in Patients Aged 6-11 Years with Severe Atopic Dermatitis: Results from a Phase III Clinical Trial
Paller AS, Wollenberg A, Siegfried E, Thaçi D, Cork MJ, Arkwright PD, Gooderham M, Sun X, O'Malley JT, Khokhar FA, Vakil J, Bansal A, Rosner K, Shumel B, Levit NA (2021)
Dupilumab Demonstrates Rapid and Consistent Improvement in Extent and Signs of Atopic Dermatitis Across All Anatomical Regions in Pediatric Patients 6 Years of Age and Older
Simpson EL, Paller AS, Siegfried EC, Thaçi D, Wollenberg A, Cork MJ, Marcoux D, Huang R, Chen Z, Rossi AB, Shumel B, Sierka D, Bansal A (2021)
Treatment outcomes of patients with Atopic Dermatitis (AD) treated with dupilumab through the Early Access to Medicines Scheme (EAMS) in the UK
O'Kane D, Davis L, Ardern-Jones M, Laws P, Shaw L, Cork M, Velangi S, Cooper HL, Hudson R, Smith AB, Rout R (2021)
Imaging striae distensae: a comparison between PS-OCT and digital dermoscopy
Lin WC, Byers RA, Li W, Danby SG, Cork MJ, Matcher SJ (2021)
A Predictive Self-Organizing Multicellular Computational Model of Infant Skin Permeability to Topically Applied Substances.
Stamatas GN, Bensaci J, Greugny E, Kaur S, Wang H, Dizon MV, Cork MJ, Friedman AJ, Oddos T (2021)
Risk of severe allergic reactions to COVID-19 vaccines among patients with allergic skin diseases - practical recommendations. A position statement of ETFAD with external experts.
Ring J, Worm M, Wollenberg A, Thyssen JP, Jakob T, Klimek L, Bangert C, Barbarot S, Bieber T, de Bruin-Weller MS, Chernyshov PV, Christen-Zaech S, Cork M, Darsow U, Flohr C, Fölster-Holst R, Gelmetti C, Gieler U, Gutermuth J, Heratizadeh A, Hijnen DJ, von Kobyletzki LB, Kunz B, Paul C, De Raeve L, Seneschal J, Simon D, Spuls PI, Stalder JF, Svensson A, Szalai Z, Taieb A, Torrelo A, Trzeciak M, Vestergaard C, Werfel T, Weidinger S, Deleuran M (2021)
European Task Force on Atopic Dermatitis (ETFAD): position on vaccination of adult patients with atopic dermatitis against COVID-19 (SARS-CoV-2) being treated with systemic medication and biologics.
Thyssen JP, Vestergaard C, Barbarot S, de Bruin-Weller MS, Bieber T, Taieb A, Seneschal J, Cork MJ, Paul C, Flohr C, Weidinger S, Trzeciak M, Werfel T, Heratizadeh A, Darsow U, Simon D, Torrelo A, Chernyshov PV, Stalder JF, Gelmetti C, Szalai Z, Svensson Å, von Kobyletzki LB, De Raeve L, Fölster-Holst R, Christen-Zaech S, Jan Hijnen D, Gieler U, Gutermuth J, Bangert C, Spuls PI, Kunz B, Ring J, Wollenberg A, Deleuran M (2021)
Skincare interventions in infants for preventing eczema and food allergy: A cochrane systematic review and individual participant data meta-analysis.
Kelleher MM, Cro S, Van Vogt E, Cornelius V, Lodrup Carlsen KC, Ove Skjerven H, Rehbinder EM, Lowe A, Dissanayake E, Shimojo N, Yonezawa K, Ohya Y, Yamamoto-Hanada K, Morita K, Cork M, Cooke A, Simpson EL, McClanahan D, Weidinger S, Schmitt J, Axon E, Tran L, Surber C, Askie LM, Duley L, Chalmers JR, Williams HC, Boyle RJ (2021)
A phase 2, open-label study of single-dose dupilumab in children aged 6 months to <6 years with severe uncontrolled atopic dermatitis: pharmacokinetics, safety and efficacy.
Paller AS, Siegfried EC, Simpson EL, Cork MJ, Lockshin B, Kosloski MP, Kamal MA, Davis JD, Sun X, Pirozzi G, Graham NMH, Gadkari A, Eckert L, Ruddy M, Bansal A (2021)
Skincare interventions in infants for preventing eczema and food allergy
Maeve M Kelleher, Suzie Cro, Victoria Cornelius, Karin C Lodrup Carlsen, Håvard O Skjerven, Eva M Rehbinder, Adrian J Lowe, Eishika Dissanayake, Naoki Shimojo, Kaori Yonezawa, Yukihiro Ohya, Kiwako Yamamoto-Hanada, Kumiko Morita, Emma Axon, Christian Surber, Michael Cork, Alison Cooke, Lien Tran, Eleanor Van Vogt, Jochen Schmitt, Stephan Weidinger, Danielle McClanahan, Eric Simpson, Lelia Duley, Lisa M Askie, Joanne R Chalmers, Hywel C Williams, Robert J Boyle (2021)
2020
Dupilumab Significantly Modulates Pain and Discomfort in Patients With Atopic Dermatitis: A Post Hoc Analysis of 5 Randomized Clinical Trials.
Silverberg JI, Simpson EL, Guttman-Yassky E, Cork MJ, de Bruin-Weller M, Yosipovitch G, Eckert L, Chen Z, Ardeleanu M, Shumel B, Hultsch T, Rossi AB, Hamilton JD, Orengo JM, Ruddy M, Graham NMH, Pirozzi G, Gadkari A (2020)
ETFAD/EADV Eczema task force 2020 position paper on diagnosis and treatment of atopic dermatitis in adults and children.
Wollenberg A, Christen-Zäch S, Taieb A, Paul C, Thyssen JP, de Bruin-Weller M, Vestergaard C, Seneschal J, Werfel T, Cork MJ, Kunz B, Fölster-Holst R, Trzeciak M, Darsow U, Szalai Z, Deleuran M, von Kobyletzki L, Barbarot S, Heratizadeh A, Gieler U, Hijnen DJ, Weidinger S, De Raeve L, Svensson Å, Simon D, Stalder JF, Ring J (2020)
The effect of water hardness on atopic eczema, skin barrier function: A systematic review, meta-analysis.
Jabbar-Lopez ZK, Ung CY, Alexander H, Gurung N, Chalmers J, Danby S, Cork MJ, Peacock JL, Flohr C (2020)
An Investigation of the Skin Barrier Restoring Effects of a Cream and Lotion Containing Ceramides in a Multi-vesicular Emulsion in People with Dry, Eczema-Prone, Skin: The RESTORE Study Phase 1
Simon G. Danby, Paul V. Andrew, Kirsty Brown, John Chittock, Linda J. Kay, Michael J. Cork (2020)
Tralokinumab for moderate-to-severe atopic dermatitis: results from two 52-week, randomized, double-blind, multicentre, placebo-controlled phase III trials (ECZTRA 1 and ECZTRA 2)
Wollenberg A, Blauvelt A, Guttman-Yassky E, Worm M, Lynde C, Lacour JP, Spelman L, Katoh N, Saeki H, Poulin Y, Lesiak A, Kircik L, Cho SH, Herranz P, Cork MJ, Peris K, Steffensen LA, Bang B, Kuznetsova A, Jensen TN, Østerdal ML, Simpson EL (2020)
Dupilumab provides favourable long-term safety and efficacy in children aged ≥ 6 to < 12 years with uncontrolled severe atopic dermatitis: results from an open-label phase IIa study and subsequent phase III open-label extension study
Cork MJ, Thaçi D, Eichenfield LF, Arkwright PD, Sun X, Chen Z, Akinlade B, Boklage S, Guillemin I, Kosloski MP, Kamal MA, O'Malley JT, Patel N, Graham NMH, Bansal A (2020)
A phase 2, open-label study of single dose dupilumab in children aged 6 months to <6 years with severe uncontrolled atopic dermatitis: pharmacokinetics, safety and efficacy
Paller AS, Siegfried EC, Simpson EL, Cork MJ, Lockshin B, Kosloski MP, Kamal MA, Davis JD, Sun X, Pirozzi G, Graham NMH, Gadkari A, Eckert L, Ruddy M, Bansal A (2020)
Efficacy and safety of abrocitinib in adults and adolescents with moderate-to-severe atopic dermatitis (JADE MONO-1): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial
Eric L. Simpson, Rodney Sinclair, Seth Forman, Andreas Wollenberg, Roland Aschoff, Michael J. Cork, Thomas Bieber, Jacob P. Thyssen, Gil Yosipovitch, Carsten Flohr, Nina Magnolo, Catherine Maari, Claire Feeney, Pinaki Biswas, Svitlana Tatulych, Hernan Valdez, Ricardo Rojo (2020)
Vehicles for atopic dermatitis therapies: more than just a placebo
Simon G. Danby, Zoe D. Draelos, Linda F. Stein Gold, Amy Cha, Bonnie Vlahos, Laraine Aikman, Paul Sanders, Dan Wu-Linhares & Michael J. Cork (2020)
Efficacy and safety of dupilumab with concomitant topical corticosteroids in children 6 to 11 years old with severe atopic dermatitis: A randomized, double-blinded, placebo-controlled phase 3 trial
Paller AS, Siegfried EC, Thaçi D, Wollenberg A, Cork MJ, Arkwright PD, Gooderham M, Beck LA, Boguniewicz M, Sher L, Weisman J, O'Malley JT, Patel N, Hardin M, Graham NMH, Ruddy M, Sun X, Davis JD, Kamal MA, Khokhar FA, Weinreich DM, Yancopoulos GD, Beazley B, Bansal A, Shumel B (2020)
European Task Force on Atopic Dermatitis (ETFAD): treatment targets and treatable traits in atopic dermatitis
Thyssen JP, Vestergaard C, Deleuran M, de Bruin-Weller MS, Bieber T, Taieb A, Seneschal J, Cork MJ, Paul C, Flohr C, Weidinger S, Trzeciak M, Werfel T, Heratizadeh A, Barbarot S, Darsow U, Simon D, Torrelo A, Chernyshov PV, Stalder JF, Gelmetti C, Szalai Z, Svensson Å, von Kobyletzki LB, De Raeve L, Fölster-Holst R, Cristen-Zaech S, Hijnen D, Gieler U, Ring J, Wollenberg A (2020)
Dupilumab reduces absenteeism in patients with moderate to severe atopic dermatitis: Pooled results from the LIBERTY AD SOLO clinical trials
de Bruin-Weller M, Simpson EL, Cork M, Chen Z, Msihid J, Taniou C, Eckert L, Gadkari A, Bégo-Le Bagousse G (2020)
European Task Force on Atopic Dermatitis statement on severe acute respiratory syndrome coronavirus 2 (SARS-Cov-2) infection and atopic dermatitis
Wollenberg A, Flohr C, Simon D, Cork MJ, Thyssen JP, Bieber T, de Bruin-Weller MS, Weidinger S, Deleuran M, Taieb A, Paul C, Trzeciak M, Werfel T, Seneschal J, Barbarot S, Darsow U, Torrelo A, Stalder JF, Svensson Å, Hijnen D, Gelmetti C, Szalai Z, Gieler U, De Raeve L, Kunz B, Spuls P, von Kobyletzki LB, Fölster-Holst R, Chernyshov PV, Christen-Zaech S, Heratizadeh A, Ring J, Vestergaard C (2020)
Daily emollient during infancy for prevention of eczema: the BEEP randomised controlled trial
Chalmers JR, Haines RH, Bradshaw LE, Montgomery AA, Thomas KS, Brown SJ, Ridd MJ, Lawton S, Simpson EL, Cork MJ, Sach TH, Flohr C, Mitchell EJ, Swinden R, Tarr S, Davies-Jones S, Jay N, Kelleher MM, Perkin MR, Boyle RJ, Williams HC; BEEP study team (2020)
Topical corticosteroid vehicle composition and implications for clinical practice
R. Oakley, B. W. M. Arents, S. Lawton, S. Danby and C. Surber (2020)
2019
Atopic dermatitis epidemiology and unmet need in the United Kingdom
Cork MJ, Danby SG, Ogg GS (2019)
Dupilumab in adolescents with uncontrolled moderate-to-severe atopic dermatitis: results from a phase IIa open-label trial and subsequent phase III open-label extension
Cork MJ, Thaçi D, Eichenfield LF, Arkwright PD, Hultsch T, Davis JD, Zhang Y, Zhu X, Chen Z, Li M, Ardeleanu M, Teper A, Akinlade B, Gadkari A, Eckert L, Kamal MA, Ruddy M, Graham NMH, Pirozzi G, Stahl N, DiCioccio AT, Bansal A (2019)
European task force on atopic dermatitis position paper: treatment of parental atopic dermatitis during preconception, pregnancy and lactation period
Vestergaard C, Wollenberg A, Barbarot S, Christen-Zaech S, Deleuran M, Spuls P, Flohr C, Trzeciak M, von Kobyletzki L, Seneschal J, Paul C, Bieber T, Werfel T, Fölster-Holst R, Darsow U, Gieler U, Svensson Å, Cork M, Stalder JF, De Raeve L, Kunz B, Simon D, Chernyshov P, Hijnen D, Gelmetti C, Ring J, Taieb A, de Bruin-Weller M, Thyssen JP (2019)
Dupilumab improves patient-reported symptoms of atopic dermatitis, symptoms of anxiety and depression, and health-related quality of life in moderate-to-severe atopic dermatitis: analysis of pooled data from the randomized trials SOLO 1 and SOLO 2
Cork MJ, Eckert L, Simpson EL, Armstrong A, Barbarot S, Puig L, Girolomoni G, de Bruin-Weller M, Wollenberg A, Kataoka Y, Remitz A, Beissert S, Mastey V, Ardeleanu M, Chen Z, Gadkari A, Chao J (2019)
Conjunctivitis in atopic dermatitis patients with and without dupilumab therapy - international eczema council survey and opinion
Thyssen JP, de Bruin-Weller MS, Paller AS, Leshem YA, Vestergaard C, Deleuran M, Drucker AM, Foelster-Holst R, Traidl-Hoffmann C, Eyerich K, Taieb A, Su JC, Bieber T, Cork MJ, Eichenfield LF, Guttman-Yassky E, Wollenberg A (2019)
Optimization of placebo use in clinical trials with systemic treatments for atopic dermatitis: an International Eczema Council survey-based position statement
Leshem YA, Bissonnette R, Paul C, Silverberg JI, Irvine AD, Paller AS, Cork MJ, Guttman-Yassky E (2019)
Conjunctivitis in dupilumab clinical trials
Akinlade B, Guttman-Yassky E, de Bruin-Weller M, Simpson EL, Blauvelt A, Cork MJ, Prens E, Asbell P, Akpek E, Corren J, Bachert C, Hirano I, Weyne J, Korotzer A, Chen Z, Hultsch T, Zhu X, Davis JD, Mannent L, Hamilton JD, Teper A, Staudinger H, Rizova E, Pirozzi G, Graham NMH, Shumel B, Ardeleanu M, Wollenberg A (2019)
Attenuation of stripe artifacts in optical coherence tomography images through wavelet-FFT filtering
Byers R, Matcher S (2019)
2018
pH in Atopic Dermatitis
Danby SG, Cork MJ (2018)
Infant Skin Barrier, Structure, and Enzymatic Activity Differ from Those of Adult in an East Asian Cohort
Liu Q, Zhang Y, Danby SG, Cork MJ, Stamatas GN (2018)
Sub-clinical assessment of atopic dermatitis severity using angiographic optical coherence tomography
Byers RA, Maiti R, Danby SG, Pang EJ, Mitchell B, Carré MJ, Lewis R, Cork MJ, Matcher SJ (2018)
Dupilumab with concomitant topical corticosteroid treatment in adults with atopic dermatitis with an inadequate response or intolerance to ciclosporin A or when this treatment is medically inadvisable: a placebo-controlled, randomized phase III clinical trial (LIBERTY AD CAFÉ)
de Bruin-Weller M, Thaçi D, Smith CH, Reich K, Cork MJ, Radin A, Zhang Q, Akinlade B, Gadkari A, Eckert L, Hultsch T, Chen Z, Pirozzi G, Graham NMH, Shumel B (2018)
The Effect of Water Hardness on Surfactant Deposition after Washing and Subsequent Skin Irritation in Atopic Dermatitis Patients and Healthy Control Subjects
Danby SG, Brown K, Wigley AM, Chittock J, Pyae PK, Flohr C, Cork MJ (2018)
Clinical Applications of Angiographic Optical Coherence Tomography
Byers, R (2018)
Biologic treatments for atopic eczema (Anti-IL-4 and IL-13 biologics)
Simon G. Danby, Andrew Wigley, Matthew J. Cork and Michael J. Cork (2018)
2017
When does atopic dermatitis warrant systemic therapy? Recommendations from an expert panel of the International Eczema Council
Simpson EL, Bruin-Weller M, Flohr C, Ardern-Jones MR, Barbarot S, Deleuran M, Bieber T, Vestergaard C, Brown SJ, Cork MJ, Drucker AM, Eichenfield LF, Foelster-Holst R, Guttman-Yassky E, Nosbaum A, Reynolds NJ, Silverberg JI, Schmitt J, Seyger MMB, Spuls PI, Stalder JF, Su JC, Takaoka R, Traidl-Hoffmann C, Thyssen JP, van der Schaft J, Wollenberg A, Irvine AD, Paller AS (2017)
Effectiveness and cost-effectiveness of daily all-over-body application of emollient during the first year of life for preventing atopic eczema in high-risk children (The BEEP trial): protocol for a randomised controlled trial
Chalmers JR, Haines RH, Mitchell EJ, Thomas KS, Brown SJ, Ridd M, Lawton S, Simpson EL, Cork MJ, Sach TH, Bradshaw LE, Montgomery AA, Boyle RJ, Williams HC (2017)
Comparison of the Simple Patient-Centric Atopic Dermatitis Scoring System PEST with SCORAD in Young Children Using a Ceramide Dominant Therapeutic Moisturizer
Koh MJ, Giam YC, Liew HM, Foong AY, Chong JH, Wong SMY, Tang MBY, Ho MSL, Tan LS, Mason JM, Cork MJ (2017)
Computational design of treatment strategies for proactive therapy on atopic dermatitis using optimal control theory
Christodoulides P, Hirata Y, Domínguez-Hüttinger E, Danby SG, Cork MJ, Williams HC, Aihara K, Tanaka RJ (2017)
Vascular patterning of subcutaneous mouse fibrosarcomas expressing individual VEGF isoforms can be differentiated using angiographic OCT
Byers R, Fisher M, Brown N, Tozer G, Matcher S (2017)
A new mode of contrast in biological second harmonic generation microscopy
Green N, Delaine-Smith R, Askew H, Byers R, Reilly G, Matcher S (2017)
Staphylococcus aureus in atopic dermatitis: a diverse problem?
Danby, S. G. (2017)
Characterizing the microcirculation of atopic dermatitis using angiographic optical coherence tomography
Byers, R. A., R. Maiti, S. G. Danby, E. J. Pang, B. Mitchell, M. J. Carré, R. Lewis, M. J. Cork and S. J. Matcher (2017)
2016
A functional mechanistic study of the effect of emollients on the structure and function of the skin barrier
Danby SG, Chalmers J, Brown K, Williams HC, Cork MJ (2016)
Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis
Simpson EL, Bieber T, Guttman-Yassky E, Beck LA, Blauvelt A, Cork MJ, Silverberg JI, Deleuran M, Kataoka Y, Lacour JP, Kingo K, Worm M, Poulin Y, Wollenberg A, Soo Y, Graham NM, Pirozzi G, Akinlade B, Staudinger H, Mastey V, Eckert L, Gadkari A, Stahl N, Yancopoulos GD, Ardeleanu M; SOLO 1 and SOLO 2 Investigators (2016)
Vitamin D and antimicrobial peptide levels in patients with atopic dermatitis and atopic dermatitis complicated by eczema herpeticum: A pilot study
Albenali LH, Danby S, Moustafa M, Brown K, Chittock J, Shackley F, Cork MJ (2016)
The Effect of an Emollient Containing Urea, Ceramide NP, and Lactate on Skin Barrier Structure and Function in Older People with Dry Skin
Danby SG, Brown K, Higgs-Bayliss T, Chittock J, Albenali L, Cork MJ (2016)
Development of stratum corneum chymotrypsin-like protease activity and natural moisturizing factors from birth to 4 weeks of age compared with adults
Chittock J, Cooke A, Lavender T, Brown K, Wigley A, Victor S, Cork MJ, Danby SG (2016)
Olive Oil, Sunflower Oil or no Oil for Baby Dry Skin or Massage: A Pilot, Assessor-blinded, Randomized Controlled Trial (the Oil in Baby SkincaRE [OBSeRvE] Study)
Cooke A, Cork MJ, Victor S, Campbell M, Danby S, Chittock J, Lavender T (2016)
In vivo measurement of skin surface strain and sub-surface layer deformation induced by natural tissue stretching
Maiti R, Gerhardt L, Lee Z, Byers R, Woods D, Franklin S, Lewis R, Matcher S, Carré M (2016)
Biological Variation in Skin Barrier Function: From A (Atopic Dermatitis) to X (Xerosis)
Danby, S. G. (2016)
2015
Comparing the Effect of a Twice-weekly Tacrolimus and Betamethasone Valerate Dose on the Subclinical Epidermal Barrier Defect in Atopic Dermatitis
Chittock J, Brown K, Cork MJ, Danby SG (2015)
Neonatal skin care and toxicology
Danby, S., C. Bedwell and M. J. Cork (2015)
2014
Emollient enhancement of the skin barrier from birth offers effective atopic dermatitis prevention
Simpson EL, Chalmers JR, Hanifin JM, Thomas KS, Cork MJ, McLean WH, Brown SJ, Chen Z, Chen Y, Williams HC (2014)
The effect of tacrolimus compared with betamethasone valerate on the skin barrier in volunteers with quiescent atopic dermatitis
Danby SG, Chittock J, Brown K, Albenali LH, Cork MJ (2014)
Hygiene and emollient interventions for maintaining skin integrity in older people in hospital and residential care settings
Cowdell, F., T. Jadotte Yuri, J. Ersser Steven, S. Danby, S. Walton, S. Lawton, A. Roberts, E. Gardiner, F. Ware and M. Cork (2014)
A new perspective on histamine in atopic dermatitis
S. Danby (2014)
2013
Improved emollient use reduces atopic eczema symptoms and is cost neutral in infants: before-and-after evaluation of a multifaceted educational support programme
Mason JM, Carr J, Buckley C, Hewitt S, Berry P, Taylor J, Cork MJ (2013)
Randomized, controlled trial evaluating a baby wash product on skin barrier function in healthy, term neonates
Lavender T, Bedwell C, Roberts SA, Hart A, Turner MA, Carter LA, Cork MJ (2013)
2012
Effect of olive and sunflower seed oil on the adult skin barrier: implications for neonatal skin care
Danby SG, AlEnezi T, Sultan A, Lavender T, Chittock J, Brown K, Cork MJ (2012)
Atopic dermatitis: a candidate for disease-modifying strategy
Bieber T, Cork M, Reitamo S (2012)
Effect on skin hydration of using baby wipes to clean the napkin area of newborn babies: assessor-blinded randomised controlled equivalence trial
Lavender T, Furber C, Campbell M, Victor S, Roberts I, Bedwell C, Cork MJ (2012)
2011
Patient education about topical treatments
Cork MJ (2011)
Aqueous cream damages the skin barrier
Cork MJ, Danby S (2011)
Infant skin-cleansing product versus water: a pilot randomized, assessor-blinded controlled trial
Lavender T, Bedwell C, O'Brien E, Cork MJ, Turner M, Hart A (2011)
The effect of aqueous cream BP on the skin barrier in volunteers with a previous history of atopic dermatitis
Danby SG, Al-Enezi T, Sultan A, Chittock J, Kennedy K, Cork MJ (2011)
Patch testing is a useful investigation in children with eczema
Moustafa M, Holden CR, Athavale P, Cork MJ, Messenger AG, Gawkrodger DJ (2011)
2010
The 3'-UTR AACCins5874 in the stratum corneum chymotryptic enzyme gene (SCCE/KLK7), associated with atopic dermatitis; causes an increased mRNA expression without altering its stability
Vasilopoulos Y, Sharaf N, di Giovine F, Simon M, Cork MJ, Duff GW, Tazi-Ahnini R (2010)
Clinical and cytological effects of pimecrolimus cream 1% after resolution of active atopic dermatitis lesions by topical corticosteroids: a randomized controlled trial
Bangert C, Strober BE, Cork M, Ortonne JP, Luger T, Bieber T, Ferguson A, Ecker RC, Kopp T, Weise-Riccardi S, Guettner A, Stingl G (2010)
A New Understanding of Atopic Dermatitis: The Role of Epidermal Barrier Dysfunction and Subclinical Inflammation
Simon G. Danby and Michael J. Cork (2010)
2009 - 1996
Epidermal barrier dysfunction in atopic dermatitis
Cork MJ, Danby SG, Vasilopoulos Y, Hadgraft J, Lane ME, Moustafa M, Guy RH, Macgowan AL, Tazi-Ahnini R, Ward SJ (2009)
A nonsynonymous substitution of cystatin A, a cysteine protease inhibitor of house dust mite protease, leads to decreased mRNA stability and shows a significant association with atopic dermatitis
Vasilopoulos Y, Cork MJ, Teare D, Marinou I, Ward SJ, Duff GW, Tazi-Ahnini R (2007)
New perspectives on epidermal barrier dysfunction in atopic dermatitis: gene-environment interactions
Cork MJ, Robinson DA, Vasilopoulos Y, Ferguson A, Moustafa M, MacGowan A, Duff GW, Ward SJ, Tazi-Ahnini R (2006)
Adverse effects of topical glucocorticosteroids
Hengge UR, Ruzicka T, Schwartz RA, Cork MJ (2006)
Safety and tolerability of 1% pimecrolimus cream among infants: experience with 1133 patients treated for up to 2 years
Paul C, Cork M, Rossi AB, Papp KA, Barbier N, de Prost Y (2005)
The development of a preference-based measure of health in children with atopic dermatitis
Stevens KJ, Brazier JE, McKenna SP, Doward LC, Cork MJ (2005)
Genetic association between an AACC insertion in the 3'UTR of the stratum corneum chymotryptic enzyme gene and atopic dermatitis
Vasilopoulos Y, Cork MJ, Murphy R, Williams HC, Robinson DA, Duff GW, Ward SJ, Tazi-Ahnini R (2004)
Comparison of parent knowledge, therapy utilization and severity of atopic eczema before and after explanation and demonstration of topical therapies by a specialist dermatology nurse
Cork MJ, Britton J, Butler L, Young S, Murphy R, Keohane SG (2003)
An audit of adverse drug reactions to aqueous cream in children with atopic eczema
Michael J. Cork, John Timmins, Catherine Holden, Julie Carr, Victoria Berry, Rachid Tazi-Ahnini, Simon J. Ward (2003)
Cyclosporin for severe childhood atopic dermatitis: short course versus continuous therapy
Harper JI, Ahmed I, Barclay G, Lacour M, Hoeger P, Cork MJ, Finlay AY, Wilson NJ, Graham-Brown RA, Sowden JM, Beard AL, Sumner MJ, Berth-Jones J (2000)
Cyclosporine in severe childhood atopic dermatitis: a multicenter study
Berth-Jones J, Finlay AY, Zaki I, Tan B, Goodyear H, Lewis-Jones S, Cork MJ, Bleehen SS, Salek MS, Allen BR, Smith S, Graham-Brown RA (1996)